-
Something wrong with this record ?
Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations
K. Mitrova, M. Julsgaard, P. Augustijns, K. Cerna, U. Mahadevan, D. Duricova, Pregnancy Study Group
Language English Country United States
Document type Journal Article
- MeSH
- Adult MeSH
- Fetal Blood * chemistry MeSH
- Janus Kinase Inhibitors therapeutic use MeSH
- Pregnancy Complications drug therapy MeSH
- Humans MeSH
- Milk, Human * chemistry MeSH
- Infant, Newborn MeSH
- Piperidines * therapeutic use MeSH
- Pyrimidines * therapeutic use MeSH
- Pregnancy MeSH
- Colitis, Ulcerative drug therapy blood MeSH
- Pregnancy Outcome * MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Infant, Newborn MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC).1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation.2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib.4-7.
Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark
Department of Pharmaceutical and Pharmacological Sciences KU Leuven Leuven Belgium
Department of Pharmacology 1st Faculty of Medicine Charles University Prague Czech Republic
GENNET s r o Prague Czech Republic
IBD Clinical and Research Centre ISCARE a s Prague Czech Republic
Immunology Department IBD Clinical and Research Centre ISCARE a s Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002954
- 003
- CZ-PrNML
- 005
- 20250206103955.0
- 007
- ta
- 008
- 250121s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cgh.2024.01.019 $2 doi
- 035 __
- $a (PubMed)38309493
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mitrova, Katarina $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; Department of Paediatrics, 2nd Faculty of Medicine, Motol University Hospital, Charles University in Prague, Prague, Czech Republic
- 245 10
- $a Tofacitinib in Pregnancy: Assessing Pregnancy and Infant Outcomes, Cord Blood, and Breast Milk Concentrations / $c K. Mitrova, M. Julsgaard, P. Augustijns, K. Cerna, U. Mahadevan, D. Duricova, Pregnancy Study Group
- 520 9_
- $a Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC).1 According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation.2-4 The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib.4-7.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a piperidiny $x terapeutické užití $7 D010880
- 650 12
- $a pyrimidiny $x terapeutické užití $7 D011743
- 650 12
- $a mateřské mléko $x chemie $7 D008895
- 650 12
- $a výsledek těhotenství $7 D011256
- 650 12
- $a fetální krev $x chemie $7 D005312
- 650 _2
- $a ulcerózní kolitida $x farmakoterapie $x krev $7 D003093
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a komplikace těhotenství $x farmakoterapie $7 D011248
- 650 _2
- $a inhibitory Janus kinas $x terapeutické užití $7 D000075242
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Julsgaard, Mette $u Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark
- 700 1_
- $a Augustijns, Patrick $u Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
- 700 1_
- $a Cerna, Karin $u Immunology Department, IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; GENNET s.r.o., Prague, Czech Republic
- 700 1_
- $a Mahadevan, Uma $u Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California
- 700 1_
- $a Duricova, Dana $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic; Department of Pharmacology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic
- 710 2_
- $a Pregnancy Study Group
- 773 0_
- $w MED00182421 $t Clinical gastroenterology and hepatology $x 1542-7714 $g Roč. 23, č. 1 (2025), s. 163-165.e3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38309493 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103951 $b ABA008
- 999 __
- $a ok $b bmc $g 2263010 $s 1238961
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 23 $c 1 $d 163-165.e3 $e 20240201 $i 1542-7714 $m Clinical gastroenterology and hepatology $n Clin Gastroenterol Hepatol $x MED00182421
- LZP __
- $a Pubmed-20250121
